Immunome Inc (IMNM) — Who's Buying and Selling (13F, Q2 2026)

IMNM ranks #2974 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

IMNM is a top-conviction position for Enavate Sciences GP, LLC — at 22.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in IMNM belongs to T. Rowe Price Investment Management, Inc., but the position matters far more to Enavate Sciences GP, LLC, who has 22.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

GAMMA Investing LLC has added to its IMNM position for two straight quarters, increasing it by $11.8K to reach $46.5K today.

Maltin Wealth Management, Inc. has trimmed its IMNM position for two straight quarters, cutting it by $126.6K while still holding $201.4K.

IMNM is down 5.3% today, but institutions show net buying of $178.4M this quarter — a divergence between today's price move and the underlying institutional flow.

IMNM reported a net loss of $254.3M over the trailing twelve months.

• Not yet profitable — net loss of $254.3M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$212.4M to -$254.3M
• Operating cash flow was negative, using $190.9M in cash
• Current ratio of 14.69x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.08x equity — within a conventional range